Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort

作者：Borek Foldyna, Thomas Mayrhofer, Markella V. Zanni, Asya Lyass, Radhika Barve, Júlia Karády, Sara McCallum, Tricia H. Burdo, Kathleen V. Fitch, Kayla Paradis, Evelynne S. Fulda, Marissa R Diggs, Gerald S. Bloomfield, Carlos Malvestutto, Carl J. Fichtenbaum, Judith A. Aberg, Judith S. Currier, Heather J. Ribaudo, Udo Hoffmann, Michael T. Lu, Pamela S. Douglas, Steven Grinspoon · 发表于：Clinical Infectious Diseases · 年份：2023 · DOI：10.1093/cid/ciad419 · 被引用次数：17 · 研究领域：Cardiovascular Disease and Adiposity、HIV-related health complications and treatments、Adipokines, Inflammation, and Metabolic Diseases

BACKGROUND: Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to coronary plaque among people with human immunodeficiency virus (HIV [PWH]) and to a matched control population. METHODS: In this baseline analysis of 727 participants of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Mechanistic Substudy, we related computed tomography-derived PCAT density to presence and extent (Leaman score) of coronary artery disease (CAD), noncalcified plaque, coronary artery calcium (CAC), and vulnerable plaque features using multivariable logistic regression analyses. We further compared the PCAT density between PWH and age, sex, body mass index, CAC score, and statin use-matched controls from the community-based Framingham Heart Study (N = 464), adjusting for relevant clinical covariates. RESULTS: Among 727 REPRIEVE participants (age 50.8 ± 5.8 years; 83.6% [608/727] male), PCAT density was higher in those with (vs without) coronary plaque, noncalcified plaque, CAC >0, vulnerable plaque, and high CAD burden (Leaman score >5) (P < .001 for each comparison). PCAT density related to prevalent coronary plaque (adjusted odds ratio [per 10 HU]: 1.44; 95% confidence interval, 1.22-1.70; P < .001), adjusted for clinical cardiovascular risk factors, body mass index, and systemic immune/inflammatory biomarkers. Similarly, PCAT density related to ...